TG Therapeutics Inc (NASDAQ:TGTX)

5.64
Delayed Data
As of 4:00pm ET
 +0.08 / +1.44%
Today’s Change
3.32
Today|||52-Week Range
9.38
+37.56%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$517.4M

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
2 Gansevoort Street
New York New York 10014
P:(212) 554-4484
Investor Relations:
1212

Employees

Shareholders

Individual stakeholders9.71%
Other institutional35.22%
Mutual fund holders17.22%

Top Executives

There are no executives to display.